Abstract
Introduction: We sought to identify and characterize distinct responder profiles among osteoarthritis (OA) subjects treated with tanezumab, nonsteroidal anti-inflammatory drugs (NSAIDs), or placebo. Methods: Subject-level data were derived from three randomized, double-blind, placebo- or NSAID-controlled trials of tanezumab in subjects with moderate-to-severe OA. Subjects received subcutaneous tanezumab (2.5 mg, n = 1527; 5 mg, n = 1279) every 8 weeks, oral NSAIDs (n = 994) daily, or placebo (n = 513). Group-based trajectory modeling (GBTM, an application of finite mixture statistical modeling that uses response trajectory to identify and summarize complex patterns in longitudinal data) was used to identify subgroups of subjects following similar patterns of response in each treatment arm, based on daily pain intensity scores from baseline through Week 16. We then examined whether subject-related variables were associated with any of the subgroups using multinomial logistic regression. Results: A three-subgroup/four-inflection point trajectory model was selected based on clinical and statistical considerations. The subgroups were high responders (substantial pain improvement and a large majority of members achieved ≥ 30% improvement before Week 16), medium responders (gradual pain improvement and a majority of members achieved ≥ 30% improvement by Week 16), and non-responders (little to no pain improvement over 16 weeks). Across all treatments, fluctuation in pain intensity in the week prior to treatment was consistently associated with treatment response. Other variables were positively (age, body mass index, days of rescue medication use) or negatively (severity of disease based on Kellgren-Lawrence grading) associated with response but effects were small and/or varied across treatments. Conclusions: Across all treatments, GBTM identified three subgroups of subjects that were characterized by extent of treatment response (high, medium, and non-responders). Similar analyses (e.g., grouping of subjects based on response trajectory and identification of subgroup-related variables) in other studies of OA could inform clinical trial design and/or treatment approaches. (NCT02697773; NCT02709486; NCT02528188).
| Original language | English (US) |
|---|---|
| Pages (from-to) | 4742-4756 |
| Number of pages | 15 |
| Journal | Advances in Therapy |
| Volume | 39 |
| Issue number | 10 |
| DOIs | |
| State | Published - Oct 2022 |
Funding
This study was funded by Pfizer and Eli Lilly and Company. The journal’s Rapid Service fee was funded by Pfizer and Eli Lilly and Company. Medical writing support was provided by Matt Soulsby, PhD, CMPP, of Engage Scientific Solutions and funded by Pfizer and Eli Lilly and Company. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published. All authors contributed to the (1) conception/design of the study and interpretation of data, (2) drafting the article or revising it critically for important intellectual content, and (3) final approval of the version to be submitted. Gianluca Bonfanti and Roger Edwards were also involved in analysis of data. Thomas J. Schnitzer reports clinical research study support from Pfizer, Lilly, Regeneron, Galapagos, Taiwan Liposome Corporation, and Anika Therapeutics and has served as a consultant or on an advisory board for Pfizer, Eli Lilly and Company, Glaxo-Smith Kline, AstraZeneca, Noven, Galapagos, and Merck. Gianluca Bonfanti is an employee of Engineering Ingegneria Informatica, a paid sub-contractor to Health Services Consulting Corporation in conjunction with this study and development of this manuscript. Joanna Atkinson is a full-time employee of Pfizer, LTD. Sean Donevan is a full-time employee of, and owns stock/options in, Pfizer Inc. Lars Viktrup is a full-time employee of, and owns stock/options in, Eli Lilly and Company. Joana Barroso has received research support from Grünenthal. Ed Whalen is a full-time employee of, and owns stock/options in, Pfizer Inc. Roger A. Edwards is an owner of Health Services Consulting Corporation, a paid consultant by Pfizer in connection with this study and development of the manuscript. The studies included in this analysis were approved by an institutional review board or independent ethics committee at each study center. All patients provided written informed consent before participating. The studies were conducted in compliance with the Declaration of Helsinki and all International Conference on Harmonization Good Clinical Practice guidelines. Please see the primary study publications for more detail. Upon request, and subject to review, Pfizer will provide the data that support the findings of this study. Subject to certain criteria, conditions, and exceptions, Pfizer may also provide access to the related individual de-identified participant data. See https://www.pfizer.com/science/clinical-trials/trial-data-and-results for more information. Medical writing support was provided by Matt Soulsby, PhD, CMPP, of Engage Scientific Solutions and funded by Pfizer and Eli Lilly and Company.
Keywords
- Group-based trajectory modeling
- Nonsteroidal anti-inflammatory drugs
- Osteoarthritis
- Pain
- Placebo
- Responder profiles
- Tanezumab
ASJC Scopus subject areas
- Pharmacology (medical)